Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Status:
Recruiting
Trial end date:
2023-08-15
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of Visudyne (liposomal
verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated
glioblastoma that has come back (recurrent).
Visudyne is FDA approved in combination with light to treat eye diseases. In this study we
use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to
verteporfin.